Digital, Blended Lifestyle Intervention for Type 2 Diabetes Remission

NCT05346614 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 410

Last updated 2022-07-20

No results posted yet for this study

Summary

410 Dutch type 2 diabetes patients will be randomized using a 5:1 ratio to intervention group versus control, to a lifestyle intervention program given via a mobile application and digital platform. Active participants will undergo diabetyping, where blood glucose and c-peptide responses to a glucose challenge are measured, and be recommended to follow a calorie-restricted (minimum 500 kcal deficit) low-carbohydrate, or restricted carbohydrate (120g) Mediterranean diet and customized exercise program for a period of 24 weeks. Individuals will then be followed for a period of 2 years following the intervention.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

BEHAVIORAL

Lifestyle intervention

Lifestyle coaching will be given on a digital app-based platform. Individuals will receive real-time feedback via a smart scale, activity monitor, and continuous glucose monitor (first 4 weeks, longer if required). Coaching will be focused on gradual behavior change, assisted by digital nudges, one-on-one, and small group coaching sessions. Coaching will include education regarding lifestyle to improve health literacy with respect to diet and diabetes management. Additionally, coaches will guide participants in the implementation of individualized diet and exercise program with varying levels of carbohydrate restriction and caloric deficit.

Sponsors & Collaborators

  • University of Groningen

    collaborator OTHER
  • Universiteit Leiden

    collaborator OTHER
  • TNO

    collaborator OTHER
  • Ancora Health B.V.

    lead INDUSTRY

Principal Investigators

  • Suzan Wopereis, PhD · TNO

  • Maarten van Aken, MD PhD · Haga Ziekenhuis

  • Elly Vogelzang, MD · Center Medische Kwartier Eindhoven

  • Janet Kist, MD · Huisartsenpraktijk Zonneoord

  • Jan Hoogsteen, MD · Ancora Health

  • Rimke Vos, PhD · Department of Public Health and Primary Care / LUMC-Campus Den Haag

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2024-06-01
Completion
2025-03-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05346614 on ClinicalTrials.gov